Article

Intraarticular Steroids for JIA May Cause Acne or Cushingoid Features

Rare systemic adverse reactions to corticosteroid injections for juvenile idiopathic arthritis are described in a review of an institution's cases and the literature.

Pediatric rheumatologists at the Rainbow Babies and Children’s Hospital in  Cleveland have alerted colleagues to rare adverse events that may after intraarticular corticosteroid injections in patients with juvenile idiopathic arthritis (JIA). They cite severe acneiform rashes, insomnia, and cushingoid features in patients profiled.

Generally, systemic absorption allows delivery of high concentrations of intraarticular corticosteroids in children, with little potential for systemic adverse events. But after the authors reviewed records at their facility, plus other reports from the literature, they found adverse events in four of 179 children injected with triamcinolone hexacetonide for JIA. These included two cases of severe acneiform rash, one of insomnia and, in a case of injection in 21 joints, cushingoid features.

While there have been reports “of general ‘Cushing-like’ appearances, there are…very few reports of specific skin and other organ/system adverse effects resulting from systemic corticosteroid absorption,” the authors report. But they recommend that rheumatologists recognize the potential for such events.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.